NS-136 is under clinical development by NeuShen Therapeutics and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NS-136’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NS-136 overview
NS-136 is under development for the treatment of schizophrenia and Alzheimer’s disease. It is being developed based on NeuChime platform technology based on artificial intelligence. It is administered through oral route. It acts by targeting muscarinic acetyl choline receptor M4.
NeuShen Therapeutics overview
NeuShen Therapeutics is an biotechnology company which focuses on psychiatric and neurological diseases and focuses to find cures to serious diseases and relieve the pain of patients and their families. NeuShen Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of NS-136’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
